Spectral takes EAA to Japan through Toray partnership:
This article was originally published in Clinica
Spectral Diagnostics has expanded its partnership with Toray Medical by appointing it as exclusive distributor of the EAA test for sepsis risk. Tokyo-headquartered Toray will market and sell Spectral's EAA system as a stand-alone product and also in conjunction with its own Toraymyxin blood purification device. The two companies have been partners over the last three years to research the use of EAA together with Toraymyxin products. Toronto, Ontario-based Spectral said that the deal will also provide it with access to other Asian countries - Toray is established in China, Indonesia, Korea, Singapore and Thailand, as well as Japan. In addition to the Toray alliance, Spectral boosted its presence in the European market this year, by signing deals with Menarini and Estor to distribute the EAA system in Germany and Italy, respectively.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.